PHARMING GROUP NV - ADR (PHAR) Stock Fundamental Analysis

NASDAQ:PHAR • US71716E1055

15.42 USD
+0.12 (+0.78%)
Last: Feb 13, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to PHAR. PHAR was compared to 523 industry peers in the Biotechnology industry. PHAR has an excellent financial health rating, but there are some minor concerns on its profitability. PHAR has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year PHAR has reported negative net income.
  • In the past year PHAR had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: PHAR reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: PHAR reported negative operating cash flow in multiple years.
PHAR Yearly Net Income VS EBIT VS OCF VS FCFPHAR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 0.08%, PHAR belongs to the top of the industry, outperforming 88.34% of the companies in the same industry.
  • With an excellent Return On Equity value of 0.14%, PHAR belongs to the best of the industry, outperforming 89.87% of the companies in the same industry.
  • The Return On Invested Capital of PHAR (7.46%) is better than 93.50% of its industry peers.
Industry RankSector Rank
ROA 0.08%
ROE 0.14%
ROIC 7.46%
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
PHAR Yearly ROA, ROE, ROICPHAR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

  • PHAR's Profit Margin of 0.11% is amongst the best of the industry. PHAR outperforms 88.53% of its industry peers.
  • PHAR's Operating Margin of 10.06% is amongst the best of the industry. PHAR outperforms 91.78% of its industry peers.
  • The Gross Margin of PHAR (89.90%) is better than 92.35% of its industry peers.
  • PHAR's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 10.06%
PM (TTM) 0.11%
GM 89.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
PHAR Yearly Profit, Operating, Gross MarginsPHAR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • PHAR has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for PHAR has been increased compared to 1 year ago.
  • PHAR has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, PHAR has an improved debt to assets ratio.
PHAR Yearly Shares OutstandingPHAR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
PHAR Yearly Total Debt VS Total AssetsPHAR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 3.82 indicates that PHAR is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.82, PHAR is in the better half of the industry, outperforming 70.55% of the companies in the same industry.
  • The Debt to FCF ratio of PHAR is 2.49, which is a good value as it means it would take PHAR, 2.49 years of fcf income to pay off all of its debts.
  • PHAR's Debt to FCF ratio of 2.49 is amongst the best of the industry. PHAR outperforms 93.31% of its industry peers.
  • A Debt/Equity ratio of 0.46 indicates that PHAR is not too dependend on debt financing.
  • The Debt to Equity ratio of PHAR (0.46) is worse than 69.98% of its industry peers.
  • Although PHAR does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 2.49
Altman-Z 3.82
ROIC/WACC1.08
WACC6.93%
PHAR Yearly LT Debt VS Equity VS FCFPHAR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • PHAR has a Current Ratio of 3.16. This indicates that PHAR is financially healthy and has no problem in meeting its short term obligations.
  • PHAR's Current ratio of 3.16 is on the low side compared to the rest of the industry. PHAR is outperformed by 62.52% of its industry peers.
  • PHAR has a Quick Ratio of 2.39. This indicates that PHAR is financially healthy and has no problem in meeting its short term obligations.
  • PHAR has a Quick ratio of 2.39. This is in the lower half of the industry: PHAR underperforms 69.79% of its industry peers.
Industry RankSector Rank
Current Ratio 3.16
Quick Ratio 2.39
PHAR Yearly Current Assets VS Current LiabilitesPHAR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 96.30% over the past year.
  • The Revenue has grown by 26.78% in the past year. This is a very strong growth!
  • PHAR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.64% yearly.
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%

3.2 Future

  • The Earnings Per Share is expected to grow by 53.48% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 8.97% on average over the next years. This is quite good.
EPS Next Y111.44%
EPS Next 2Y85.83%
EPS Next 3Y65.17%
EPS Next 5Y53.48%
Revenue Next Year26.31%
Revenue Next 2Y14.87%
Revenue Next 3Y10.89%
Revenue Next 5Y8.97%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
PHAR Yearly Revenue VS EstimatesPHAR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
PHAR Yearly EPS VS EstimatesPHAR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 -1 1.5

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • PHAR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Based on the Price/Forward Earnings ratio of 81.76, the valuation of PHAR can be described as expensive.
  • 88.15% of the companies in the same industry are more expensive than PHAR, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 27.96. PHAR is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 81.76
PHAR Price Earnings VS Forward Price EarningsPHAR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -500 -1K -1.5K

4.2 Price Multiples

  • 94.26% of the companies in the same industry are more expensive than PHAR, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, PHAR is valued cheaply inside the industry as 95.60% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 20.43
EV/EBITDA 19.15
PHAR Per share dataPHAR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4 5

4.3 Compensation for Growth

  • PHAR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of PHAR may justify a higher PE ratio.
  • PHAR's earnings are expected to grow with 65.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y85.83%
EPS Next 3Y65.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PHAR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHARMING GROUP NV - ADR

NASDAQ:PHAR (2/13/2026, 8:00:00 PM)

15.42

+0.12 (+0.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-12
Inst Owners21.51%
Inst Owner Change-3.6%
Ins Owners1.39%
Ins Owner ChangeN/A
Market Cap1.07B
Revenue(TTM)362.27M
Net Income(TTM)383.00K
Analysts88.57
Price Target18.18 (17.9%)
Short Float %0.03%
Short Ratio0.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)597.09%
Min EPS beat(2)123.3%
Max EPS beat(2)1070.87%
EPS beat(4)2
Avg EPS beat(4)281.14%
Min EPS beat(4)-42.39%
Max EPS beat(4)1070.87%
EPS beat(8)3
Avg EPS beat(8)65.03%
EPS beat(12)5
Avg EPS beat(12)12.9%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.89%
Min Revenue beat(2)1.11%
Max Revenue beat(2)8.68%
Revenue beat(4)4
Avg Revenue beat(4)8.65%
Min Revenue beat(4)1.11%
Max Revenue beat(4)13.37%
Revenue beat(8)5
Avg Revenue beat(8)1.62%
Revenue beat(12)7
Avg Revenue beat(12)-0.52%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.56%
PT rev (3m)21.7%
EPS NQ rev (1m)37.78%
EPS NQ rev (3m)239.96%
EPS NY rev (1m)-91.66%
EPS NY rev (3m)-93.56%
Revenue NQ rev (1m)1.64%
Revenue NQ rev (3m)9.47%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 81.76
P/S 2.97
P/FCF 20.43
P/OCF 20.19
P/B 4.06
P/tB 8.28
EV/EBITDA 19.15
EPS(TTM)-0.01
EYN/A
EPS(NY)0.19
Fwd EY1.22%
FCF(TTM)0.75
FCFY4.89%
OCF(TTM)0.76
OCFY4.95%
SpS5.2
BVpS3.8
TBVpS1.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.08%
ROE 0.14%
ROCE 9.44%
ROIC 7.46%
ROICexc 13.1%
ROICexgc 33.95%
OM 10.06%
PM (TTM) 0.11%
GM 89.9%
FCFM 14.51%
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
F-Score7
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 2.49
Debt/EBITDA 2.33
Cap/Depr 4%
Cap/Sales 0.17%
Interest Coverage 5.94
Cash Conversion 102.18%
Profit Quality 13727.2%
Current Ratio 3.16
Quick Ratio 2.39
Altman-Z 3.82
F-Score7
WACC6.93%
ROIC/WACC1.08
Cap/Depr(3y)9.71%
Cap/Depr(5y)59.68%
Cap/Sales(3y)0.61%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
EPS Next Y111.44%
EPS Next 2Y85.83%
EPS Next 3Y65.17%
EPS Next 5Y53.48%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%
Revenue Next Year26.31%
Revenue Next 2Y14.87%
Revenue Next 3Y10.89%
Revenue Next 5Y8.97%
EBIT growth 1Y355.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year401.72%
EBIT Next 3Y93.29%
EBIT Next 5Y78.86%
FCF growth 1Y309.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y325.01%
OCF growth 3YN/A
OCF growth 5YN/A

PHARMING GROUP NV - ADR / PHAR FAQ

Can you provide the ChartMill fundamental rating for PHARMING GROUP NV - ADR?

ChartMill assigns a fundamental rating of 6 / 10 to PHAR.


What is the valuation status for PHAR stock?

ChartMill assigns a valuation rating of 6 / 10 to PHARMING GROUP NV - ADR (PHAR). This can be considered as Fairly Valued.


Can you provide the profitability details for PHARMING GROUP NV - ADR?

PHARMING GROUP NV - ADR (PHAR) has a profitability rating of 6 / 10.


Can you provide the financial health for PHAR stock?

The financial health rating of PHARMING GROUP NV - ADR (PHAR) is 7 / 10.